Welcome to our dedicated page for Regen Biopharma news (Ticker: RGBP), a resource for investors and traders seeking the latest updates and insights on Regen Biopharma stock.
Regen BioPharma, Inc. (RGBP) generates news primarily around its development of HemaXellerate and its broader immunology and immunotherapy pipeline. Company press releases and third-party research coverage describe Regen BioPharma as a biotechnology issuer focused on autologous cell therapies, RNA and DNA-based therapeutics, RNA vaccines, and small molecule drugs for cancer, autoimmune disorders, and hematological conditions.
A central theme in recent RGBP news is the progression of HemaXellerate, a stem cell-derived, autologous cellular therapy designed to stimulate bone marrow regeneration. Regen BioPharma has announced FDA IND clearance for a planned Phase I clinical trial in aplastic anemia, updates on its Orphan Drug Application for this indication, and plans to present these developments at investor conferences such as the Emerging Growth Conference. Additional releases discuss potential expansion of HemaXellerate into chemotherapy-induced bone marrow suppression and describe its intended multi-lineage regenerative effects on blood cell production.
News items also cover Regen BioPharma’s participation in virtual investor events, where management outlines scientific goals, timelines for moving HemaXellerate into clinical testing, and progress on preclinical programs including mRNA and small molecule therapies. Third-party research reports highlighted in press releases review the company’s transition from preclinical to clinical-stage development, its intellectual property position, and its multiple filed INDs.
Investors following RGBP news can expect updates on regulatory milestones, such as responses to FDA comments on orphan designation, details of planned Phase I trial design, collaborations with clinical research organizations, and historical disclosures about financing activities and share issuances. Bookmarking this page provides a centralized view of Regen BioPharma’s evolving clinical plans, regulatory interactions, and pipeline-related announcements.
Regen BioPharma, Inc. (OTC-PINK: RGBP, RGBPP) will present at the Emerging Growth Conference on November 9, 2022, from 1:45 - 2:15 PM Eastern Time. This live, interactive event allows investors to engage with CEO Dr. David Koos in real time. The company focuses on biotechnology, advancing therapies including RNA vaccines and small molecule drugs. Registration is available via the conference website, and an archived version will be accessible afterward. This event aims to enhance communication between Regen BioPharma and its shareholders.
Regen BioPharma, Inc. (OTC PINK: RGBP) has initiated a program to expedite the clinical development of its NR2F6 therapies by integrating modified mRNA technology with its existing siRNA intellectual property. The company has submitted an Investigational New Drug Application (IND#16928) for its drug tCellVax, designed to silence NR2F6 in human immune cells to enhance their ability to combat cancer. Regen has engaged Dyo Biotechnologies for support in this development, and is developing a new patent application to protect its innovations.
Oncology Pharma (OTC PINK:ONPH) and Regen BioPharma (OTC PINK:RGBP, RGBPP) announced a collaboration to accelerate the development of therapeutic mRNA vaccines for treating pancreatic cancer. ONPH has exclusive rights to the commercial development of these vaccines, which utilize modified mRNA to boost the immune response against cancer. The joint effort will focus on IND-enabling studies, with Regen providing scientific expertise. The project faces contingencies including securing financing and final agreement terms. The advancement of this technology could positively impact pancreatic cancer treatment.
Regen BioPharma, Inc. (RGBP, RGBPP) is launching a development program for its modified mRNA anti-cancer vaccine targeting the Survivin protein. The initial phase includes pre-clinical studies essential for an FDA IND submission. This patented technology involves using modified mRNA to produce Survivin peptides that activate dendritic cells, aiming to combat cancer effectively. Survivin's role in inhibiting cell death makes it a critical target for cancer therapies. CEO David Koos expressed optimism about advancing this technology, especially with potential applications beyond pancreatic cancer.
Regen BioPharma (PINK: RGBP, RGBPP) has made significant strides under CEO David R. Koos since March 2021, overcoming financial and legal challenges. The company revived valuable intellectual property, settled a $1.2M lawsuit, and became current with SEC filings, safeguarding its public trading status. In Q3 2021, Regen generated $1.9M from licensing agreements, although revenue accounting will be adjusted per ASC 606. Looking ahead, Koos aims to secure more collaborations to advance clinical trials without drawing a salary, reflecting his commitment to the company’s future.
Regen BioPharma (PINK: RGBP, RGBPP) has announced a strategic shift towards in-vitro diagnostics, focusing on regenerative medicine. The company has entered a non-binding Letter of Intent to acquire Canary Oncoceutics, a firm developing precision oncology tests. This acquisition is contingent on due diligence and a crucial need for $50 million in funding to support development. Canary’s innovative technology aims to enhance cancer treatment by personalizing drug recommendations based on individual tumor responses. The global cancer diagnostics market is projected to grow from $168 billion in 2020 to $280 billion by 2028.